Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: We agree with Drs Taylor and Fontana that the safety and efficacy of transplanting organs from donors seropositive for HCV might vary with different organ type. Although our study suggests that the use of HCV-positive donors conveys an early and sustained survival disadvantage among heart transplant recipients, other studies suggest similar patient survival among liver transplant recipients1 and differences in survival only after 3 to 5 years posttransplant among kidney transplant recipients.2 In contrast, little is known about the consequences of transplanting lung, pancreas, and intestinal allografts from HCV-positive donors.
Gasink LB, Blumberg EA, Localio AR, Lautenbach E, Desai SS, Israni AK. Hepatitis C in Organ Donors and Heart Transplant Recipients—Reply. JAMA. 2007;297(7):696–697. doi:10.1001/jama.297.7.696-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: